424 related articles for article (PubMed ID: 7949179)
1. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.
Inoue K; Sugiyama H; Ogawa H; Nakagawa M; Yamagami T; Miwa H; Kita K; Hiraoka A; Masaoka T; Nasu K
Blood; 1994 Nov; 84(9):3071-9. PubMed ID: 7949179
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels.
Inoue K; Ogawa H; Yamagami T; Soma T; Tani Y; Tatekawa T; Oji Y; Tamaki H; Kyo T; Dohy H; Hiraoka A; Masaoka T; Kishimoto T; Sugiyama H
Blood; 1996 Sep; 88(6):2267-78. PubMed ID: 8822948
[TBL] [Abstract][Full Text] [Related]
3. [WT 1 and leukemia].
Inoue K; Sugiyama H
Rinsho Ketsueki; 1995 Jun; 36(6):552-8. PubMed ID: 7643450
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
Miyamura T; Sakata N; Okamura T; Yasui M; Inoue M; Yagi K; Sako M; Komada Y; Matsuyama T; Oda M; Park YD; Kawa K
Int J Hematol; 2004 Apr; 79(3):243-9. PubMed ID: 15168592
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. The Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho).
Fukutani H; Naoe T; Ohno R; Yoshida H; Kiyoi H; Miyawaki S; Morishita H; Sano F; Kamibayashi H; Matsue K
Leukemia; 1995 Apr; 9(4):588-93. PubMed ID: 7723389
[TBL] [Abstract][Full Text] [Related]
6. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
7. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
[TBL] [Abstract][Full Text] [Related]
8. [The importance of WT1 gene expression in the detection of minimal residual disease. A comparison of WT1 AML1/MTG8 transcripts].
Kusumoto S; Murohashi I; Bessho M; Matsumoto H; Shimazu M
Rinsho Ketsueki; 1999 Jun; 40(6):511-4. PubMed ID: 10422290
[TBL] [Abstract][Full Text] [Related]
9. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.
Bergmann L; Miething C; Maurer U; Brieger J; Karakas T; Weidmann E; Hoelzer D
Blood; 1997 Aug; 90(3):1217-25. PubMed ID: 9242555
[TBL] [Abstract][Full Text] [Related]
10. Utility of WT1 as a reliable tool for the detection of minimal residual disease in children with leukemia.
Kletzel M; Olzewski M; Huang W; Chou PM
Pediatr Dev Pathol; 2002; 5(3):269-75. PubMed ID: 12007019
[TBL] [Abstract][Full Text] [Related]
11. Detection of minimal residual disease in a patient with acute promyelocytic leukemia by RT-PCR: necessity of chemotherapy following ATRA therapy.
Sun T; Takatsuki H; Yamashita S; Yufu Y; Umemura T; Nishimura J; Nawata H
Fukuoka Igaku Zasshi; 1994 Feb; 85(2):52-6. PubMed ID: 8144129
[TBL] [Abstract][Full Text] [Related]
12. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.
Menssen HD; Renkl HJ; Rodeck U; Maurer J; Notter M; Schwartz S; Reinhardt R; Thiel E
Leukemia; 1995 Jun; 9(6):1060-7. PubMed ID: 7596170
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse.
Grimwade D; Howe K; Langabeer S; Burnett A; Goldstone A; Solomon E
Leukemia; 1996 Jan; 10(1):61-6. PubMed ID: 8558940
[TBL] [Abstract][Full Text] [Related]
14. Quantification of WT1 mRNA by competitive NASBA in AML patients.
Fukahori S
Kurume Med J; 2001; 48(2):129-34. PubMed ID: 11501493
[TBL] [Abstract][Full Text] [Related]
15. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.
Willasch AM; Gruhn B; Coliva T; Kalinova M; Schneider G; Kreyenberg H; Steinbach D; Weber G; Hollink IH; Zwaan CM; Biondi A; van der Velden VH; Reinhardt D; Cazzaniga G; Bader P; Trka J;
Leukemia; 2009 Aug; 23(8):1472-9. PubMed ID: 19322206
[TBL] [Abstract][Full Text] [Related]
16. [Genetic diagnosis of leukemia: diagnosis of relapse and complete remission, and prediction of leukemia onset].
Sugiyama H
Rinsho Byori; 2000 Feb; 48(2):155-61. PubMed ID: 10804819
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia].
Kim HR; Shin JH; Lee JN; Lee EY
Korean J Lab Med; 2007 Oct; 27(5):305-12. PubMed ID: 18094593
[TBL] [Abstract][Full Text] [Related]
18. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
19. Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia.
Sugiyama H
Leuk Lymphoma; 1998 Jun; 30(1-2):55-61. PubMed ID: 9669676
[TBL] [Abstract][Full Text] [Related]
20. [Expression of the Wilms' Tumor Gene WT1 and Detection of Minimal Residual Disease in Acute Leukemia].
Fu J; Wang L; Wang W; Chen Z
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2000 Sep; 8(3):211-215. PubMed ID: 12578685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
